COVID-19 Rebound After Paxlovid Treatment: A Case Series and Review of Literature
Shatha Alshanqeeti, Ashish Bhargava
Abstract
Since the declaration of COVID-19 as a pandemic in 2020, several therapies have been developed to reduce symptoms of COVID-19 infection and prevent progression. Paxlovid is an antiviral that was authorized for emergency use in December 2021 for non-hospitalized symptomatic patients with COVID-19 to prevent progression to severe disease. Relapse of symptoms following a period of improvement after treatment with Paxlovid has been described recently. Data are limited, but the disease course in available case reports is usually mild and requires no additional antiviral treatment. We present the cases of COVID-19 relapse (COVID-19 rebound) in two patients following treatment with Paxlovid.
Topics & Concepts
MedicineCoronavirus disease 2019 (COVID-19)Pandemic2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)DiseaseSymptomatic treatmentIntensive care medicineAntiviral treatmentDeclarationPediatricsInternal medicineVirologyVirusInfectious disease (medical specialty)OutbreakLawChronic hepatitisPolitical scienceSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesViral Infections and Immunology Research